AG2R LA Mondiale Gestion D Actifs Makes New $1.54 Million Investment in GE HealthCare Technologies Inc. $GEHC

Key Points

• AG2R LA Mondiale Gestion D Actifs made a new investment of $1.54 million in GE HealthCare Technologies, acquiring 19,085 shares of the company in the 1st quarter.
• GE HealthCare Technologies reported a quarterly earnings per share (EPS) of $1.06, exceeding the consensus estimate, and had a revenue of $5 billion for the quarter.
• Several analysts upgraded GE HealthCare Technologies' stock rating, with Wall Street Zen moving it from "hold" to "buy" and setting an average price target of $88.40.

AG2R LA Mondiale Gestion D Actifs acquired a new position in GE HealthCare Technologies Inc. (NASDAQ:GEHC - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 19,085 shares of the company's stock, valued at approximately $1,540,000.

Several other hedge funds also recently modified their holdings of the stock. D. E. Shaw & Co. Inc. raised its position in GE HealthCare Technologies by 44.8% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 25,810 shares of the company's stock valued at $2,018,000 after buying an additional 7,980 shares during the last quarter. Janus Henderson Group PLC raised its position in GE HealthCare Technologies by 21.4% in the 4th quarter. Janus Henderson Group PLC now owns 62,620 shares of the company's stock valued at $4,895,000 after buying an additional 11,041 shares during the last quarter. OMERS ADMINISTRATION Corp raised its position in GE HealthCare Technologies by 22.3% in the 4th quarter. OMERS ADMINISTRATION Corp now owns 17,354 shares of the company's stock valued at $1,357,000 after buying an additional 3,167 shares during the last quarter. NorthRock Partners LLC raised its position in GE HealthCare Technologies by 127.0% in the 4th quarter. NorthRock Partners LLC now owns 6,253 shares of the company's stock valued at $489,000 after buying an additional 3,498 shares during the last quarter. Finally, Quantinno Capital Management LP raised its position in GE HealthCare Technologies by 25.7% in the 4th quarter. Quantinno Capital Management LP now owns 36,040 shares of the company's stock valued at $2,818,000 after buying an additional 7,379 shares during the last quarter. Hedge funds and other institutional investors own 82.06% of the company's stock.

GE HealthCare Technologies Price Performance

GE HealthCare Technologies stock opened at $76.44 on Friday. GE HealthCare Technologies Inc. has a 12 month low of $57.65 and a 12 month high of $94.80. The company has a current ratio of 1.16, a quick ratio of 0.93 and a debt-to-equity ratio of 0.85. The business's 50 day simple moving average is $74.46 and its 200 day simple moving average is $73.54. The company has a market cap of $34.90 billion, a price-to-earnings ratio of 15.66, a PEG ratio of 2.98 and a beta of 1.13.

GE HealthCare Technologies (NASDAQ:GEHC - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The company reported $1.06 EPS for the quarter, beating the consensus estimate of $0.91 by $0.15. GE HealthCare Technologies had a return on equity of 23.93% and a net margin of 11.22%.The business had revenue of $5 billion for the quarter, compared to the consensus estimate of $4.96 billion. During the same quarter in the prior year, the business earned $1.00 earnings per share. GE HealthCare Technologies's revenue for the quarter was up 3.5% on a year-over-year basis. GE HealthCare Technologies has set its FY 2025 guidance at 4.430-4.630 EPS. Sell-side analysts forecast that GE HealthCare Technologies Inc. will post 4.68 EPS for the current year.

GE HealthCare Technologies Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, August 15th. Investors of record on Friday, July 25th were paid a $0.035 dividend. The ex-dividend date was Friday, July 25th. This represents a $0.14 annualized dividend and a yield of 0.2%. GE HealthCare Technologies's dividend payout ratio is presently 2.87%.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Wall Street Zen raised shares of GE HealthCare Technologies from a "hold" rating to a "buy" rating in a research report on Saturday, May 31st. Zacks Research raised shares of GE HealthCare Technologies from a "hold" rating to a "strong-buy" rating in a research report on Thursday, August 28th. Citigroup lifted their target price on shares of GE HealthCare Technologies from $89.00 to $93.00 and gave the stock a "buy" rating in a research report on Thursday, July 31st. BTIG Research reissued a "buy" rating on shares of GE HealthCare Technologies in a research report on Monday, July 14th. Finally, Morgan Stanley dropped their target price on shares of GE HealthCare Technologies from $78.00 to $74.00 and set an "equal weight" rating on the stock in a research report on Thursday, July 31st. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $88.40.

About GE HealthCare Technologies

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.

Want to see what other hedge funds are holding GEHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GE HealthCare Technologies Inc. (NASDAQ:GEHC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.